{Reference Type}: Journal Article
{Title}: Carcinoid crisis: The challenge is still there.
{Author}: Guerrero-Pérez F;Peiró I;Vercher-Conejero JL;Teulé A;Villabona C;
{Journal}: Endocrinol Diabetes Nutr (Engl Ed)
{Volume}: 71
{Issue}: 6
{Year}: 2024 Jun-Jul
{Factor}: 1.833
{DOI}: 10.1016/j.endien.2024.03.020
{Abstract}: Carcinoid crisis (CC) has classically been considered the extreme end of the spectrum of carcinoid syndrome (CS). However, this presumption and other aspects of CC remain poorly understood. Consequently, current clinical guidelines are based on a low quality of evidence. There is no standard definition of CC and its incidence is unknown. Patients with florid CS and elevated serotonin (or its derivatives) which develop CC have been reported during decades. Nevertheless, the hypothesis that CC is due to the sudden massive release of serotonin or other vasoactive substances is unproven. Many triggers of CC (surgery, anaesthesia, peptide receptor radionuclide therapy, tumour biopsy or liver-directed treatments) have been proposed. However, data from studies are heterogeneous and even contradictory. Finally, the role of octreotide in the prevention of CC has been questioned. Herein, we report a clinical case and perform a critical review of the evidence available today on this topic.